Add like
Add dislike
Add to saved papers

Epithelial insulin receptor expression-prognostic relevance in colorectal cancer.

Oncotarget 2018 December 26
Background: Metabolic reprogramming in cancer encompasses the insulin receptor (IR) as a player of energy homeostasis and proliferation. We aimed to characterize vascular (VIR) and epithelial (EIR) IR expression in CRC and correlate it with clinico-pathological parameters and survival.

Methods: 1580 primary CRCs were explored by immunohistochemistry for evaluation of VIR and EIR. Subgroup analyses included in situ hybridization for IR isoform A (IR-A) and DNA mismatch repair protein immunohistochemistry. Clinico-pathological and survival parameters were studied.

Results: High VIR was evident in 63.5% of all CRC samples and was associated with T-stage ( P = 0.005). EIR was present in 72.2% and was associated with lower T-stages ( P = 0.006) and UICC-stages ( P < 0.001). EIR negativity was associated with increased metastasis ( P = 0.028), nodal spread ( P < 0.001), lymphatic invasion ( P = 0.008) and a decreased tumor-specific ( P = 0.011) and overall survival ( P = 0.007; 95%-C.I.: 44.5-84.1). EIR negativity in UICC-stage II was associated with a significantly worse tumor-specific ( P = 0.045) and overall ( P = 0.043) survival. IR-A was expressed in CRC vessels and cells.

Conclusions: We demonstrate VIR to be frequent in CRC and characterize EIR negativity as an important prognostic risk factor. The association between EIR negativity and worse survival in UICC-stage II should be prospectively evaluated for an application in therapeutic algorithms.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app